SOURCE: RayBiotech, Inc

RayBiotech, Inc. Announces Master Services and Supply Agreement With Colorado State University

NORCROSS, GA, Dec 10, 2013 - RayBiotech, Inc. ("RBI") today announced that it has executed a formal master services and supply agreement with the Proteomics and Metabolomics Core Facility of Colorado State University in Fort Collin, Colorado. Under the terms of the agreement, RayBiotech will provide biomarker discovery and characterization services and products to Colorado State University researchers located campus-wide. These services and products are based upon RayBiotech's antibody array and ELISA technologies and will be provided under preferred pricing arrangements. All services will be implemented under Good Laboratory Practices (GLP) compliance and all products are manufactured under Good Manufacturing Practices (GMP) compliance and ISO 13485: 2003 certification. Financial terms were not disclosed.

 

RayBiotech's President, Chief Operating Officer and Co-founder, Ms. Rani Huang, commented, "The Proteomics and Metabolomics Core Facility at Colorado State University is one of the leading biochemical pathway characterization cores nationwide. We are delighted to have the opportunity to provide comprehensive biomarker analysis services and products to the CSU Core under preferred pricing, and we look forward to making a significant impact on biomarker characterization efforts by all CSU researchers." 

 

Dr. Jessica Prenni, Director of the Proteomics and Metabolomics Core at Colorado State University, stated, "RayBiotech's portfolio of antibody array and ELISA-related services and products perfectly complements the objectives of our core facility. This master services and supply partnership will provide yet new avenues for CSU researchers to discover and study key biomarkers of physiology and disease."

 

About RayBiotech, Inc.
In 2001 RayBiotech (http://www.raybiotech.com) introduced the first commercially available cytokine antibody array. With a focus on translating scientific knowledge into improved health, RayBiotech continues to pioneer advances in high-throughput platforms for identifying disease mechanisms, screening and validation of biomarkers and identification of drug targets. RayBiotech products are manufactured under GMP compliance and ISO 13485: 2003 certification and are featured in thousands of publications, including: Nature, Nature Medicine, Science, Cell, Lancet, PNAS and many others. Offering the largest selection of protein arrays, RayBiotech has established a reputation for high quality and innovation in the research community. A spin-off from Emory University, RayBiotech is privately owned, with headquarters in metro Atlanta (Norcross, GA).

 

For More Information:

Rob Burgess, PhD
Vice President, Global Business Development 
RayBiotech, Inc. 
Phone: 770-729-2992 
Email: rob@raybiotech.com

 

 

SOURCE: RayBiotech, Inc.